MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 40 - 65 |
| Updated: | 7/18/2018 |
| Start Date: | August 25, 2016 |
| End Date: | March 2019 |
Understanding Exercise Intolerance After Treatment for Cancer
This pilot research trial studies magnetic resonance imaging (MRI) and cardio
(heart)-pulmonary (lung) exercise testing in evaluating exercise intolerance in patients with
stage I-III breast cancer after treatment with chemotherapy drugs called anthracyclines.
Anthracyclines are related with heart problems, cardiac abnormalities, bone and muscle
dysfunction. Patients with breast cancer who are exposed to anthracycline drugs may also
experience progressive fatigue and exercise intolerance which may limit daily activities and
is an important barrier for patients returning to work. Using MRI and cardio-pulmonary
exercise testing (CPET) may help doctors understand the causes of fatigue and exercise
intolerance in patients receiving anthracycline chemotherapy and this may also allow doctors
to plan better treatments to protect patients' heart, cardiovascular system, bone and muscle
function.
(heart)-pulmonary (lung) exercise testing in evaluating exercise intolerance in patients with
stage I-III breast cancer after treatment with chemotherapy drugs called anthracyclines.
Anthracyclines are related with heart problems, cardiac abnormalities, bone and muscle
dysfunction. Patients with breast cancer who are exposed to anthracycline drugs may also
experience progressive fatigue and exercise intolerance which may limit daily activities and
is an important barrier for patients returning to work. Using MRI and cardio-pulmonary
exercise testing (CPET) may help doctors understand the causes of fatigue and exercise
intolerance in patients receiving anthracycline chemotherapy and this may also allow doctors
to plan better treatments to protect patients' heart, cardiovascular system, bone and muscle
function.
PRIMARY OBJECTIVES:
I. To determine the feasibility of performing upright treadmill cardio-pulmonary exercise
stress testing utilizing magnetic resonance imaging.
II. To determine the reproducibility of measures of peak oxygen uptake (V02) and cardiac
output as well as arterio-venous oxygen difference (A-V02) difference in survivors of breast
cancer treatment and control participants.
OUTLINE:
Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart.
Patients also undergo MRI before and within 60 seconds after exercising.
I. To determine the feasibility of performing upright treadmill cardio-pulmonary exercise
stress testing utilizing magnetic resonance imaging.
II. To determine the reproducibility of measures of peak oxygen uptake (V02) and cardiac
output as well as arterio-venous oxygen difference (A-V02) difference in survivors of breast
cancer treatment and control participants.
OUTLINE:
Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart.
Patients also undergo MRI before and within 60 seconds after exercising.
Inclusion Criteria:
- Women with stage I-III breast cancer who began their cancer treatment 1-2 years prior
to this study and have received anthracycline based chemotherapy
- Women matched to age with our 16 post-cancer treatment participants
Exclusion Criteria:
- Those with contraindications for MRI such as ferromagnetic cerebral aneurysm clips or
other intracranial metal, pacemakers, defibrillators, functioning neurostimulator
devices or other implanted electronic devices
- Those with contraindications for exercise tolerance test (ETT) testing, including
unstable angina or inability to exercise on a treadmill or stationary cycle
- Those who are pregnant, claustrophobic, or unable to provide informed consent
We found this trial at
1
site
Medical Center Boulevard
Winston-Salem, North Carolina 27157
Winston-Salem, North Carolina 27157
336-716-2255
Principal Investigator: William G. Hundley
Phone: 336-716-0607
Comprehensive Cancer Center of Wake Forest University Our newly expanded Comprehensive Cancer Center is the...
Click here to add this to my saved trials
